Biosyent Inc (RX)

[valuemind]

I think that it would eventually reach $5, due to the following 3 reasons:
1)Excluding $82,000 one time expense related to conditionally recoverable license fees from the Company prudent accounting policy, the Company would have earned total comprehensive income of $317,998 or $0.0223 per fully diluted shares during Q3, 2011;
2)Sales grew about 60% last quarter, and it will continue to grow at similar rate in the forseeable future considering Feramax's huge growth potential and its new product pipeline;
3) the company produces more and more cash quarter after quareter with no debt.